XERIS BIOPHARMA HOLDINGS, INC. Deferred Compensation Arrangement with Individual, Compensation Expense
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Deferred Compensation Arrangement with Individual, Compensation Expense of $1.60 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-11.
Discontinued › Expense Statement › Operating Expenses
us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense · last filed 2024-03-06
- XERIS BIOPHARMA HOLDINGS, INC. deferred compensation arrangement with individual, compensation expense for the quarter ending 2022-03-31 was $1.60M.
- XERIS BIOPHARMA HOLDINGS, INC. deferred compensation arrangement with individual, compensation expense for fiscal 2021 was $1.60M.
| Period end | Deferred Compensation Arrangement with Individual, Compensation Expense 3 month | Deferred Compensation Arrangement with Individual, Compensation Expense 12 month |
|---|---|---|
| 2022-03-31 | $1.60M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $1.60M 10-K · filed 2024-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |